分子量:50 kDa

纯度:>95% as determined by SEC-HPLC and SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the Human B7-1, Fc Tag (HPLC-verified) by the LAL method.

Buffer:50 mM tris, 100 mM glycine, pH7.5

生物活性:Measured by its ability to induce IL-2 secretion by Jurkat human acute T cell leukemia cells.TheED50 forthiseffectistypically0.025 - 0.15g/mLinthepresenceofPHA.
Measured by its binding ability in a functional ELISA. Immobilized Human B7-1, Fc Tag (HPLC-verified) (Catalog # B71-H5259) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4 (Catalog # CT4-H82E4) with a linear range of 50 - 500 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized Human B7-1, Fc Tag (HPLC-verified) (Catalog # B71-H5259) at 2 μg/mL ( 100 μl/well ) can bind Human CTLA-4, Strep Tag (Catalog # CT4-H5284) with a linear range of 1-20 ng/mL.

产品特性:Human B7-1, Fc Tag (HPLC-verified) is fused with a human IgG1 Fc tag at the C-terminus, and has a calculated MW of 50 kDa. The predicted N-terminus is Val 35. The reducing (R) protein migrates as 70-90 kDa in SDS-PAGE  due to glycosylation.

产品背景:B71 and B72, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20  100 fold higher affinity than CD28 and is involved in the downregulation of the immune response.
B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80  (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activatedBcells,activatedTcells,macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.